Cellectar Biosciences, Inc. (CLRB)

NASDAQ: CLRB · Real-Time Price · USD

0.2920

-0.0233 (-7.39%)

At close: Apr 1, 2025, 4:00 PM

0.2965

+0.0045 (1.54%)

After-hours: Apr 1, 2025, 4:24 PM EDT

Cellectar Biosciences Stock Forecast

CLRB's stock price has decreased by -92.16% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Cellectar Biosciences stock has a target of 28, which predicts an increase of 9,489.04% from the current stock price of 0.29.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$28	$28	$28	$28
Change	+9489.0%	+9489.0%	+9489.0%	+9489.0%

* Price targets were last updated on Mar 28, 2024.

Analyst Ratings

The average analyst rating for Cellectar Biosciences stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	1	1	1	1	1	1
Buy	1	1	0	0	0	0
Hold	0	0	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jeff Jones Oppenheimer	Oppenheimer	Buy → Hold Downgrades n/a	Buy → Hold	Downgrades	n/a	n/a	Dec 11, 2024
Jeff Jones Oppenheimer	Oppenheimer	Buy Maintains $14 → $12	Buy	Maintains	$14 → $12	+4,009.59%	Nov 19, 2024
Jeff Jones Oppenheimer	Oppenheimer	Buy Reiterates $14	Buy	Reiterates	$14	+4,694.52%	Oct 11, 2024
Jonathan Aschoff Roth MKM	Roth MKM	Strong Buy Maintains $20 → $28	Strong Buy	Maintains	$20 → $28	+9,489.04%	Mar 28, 2024
Jeff Jones Oppenheimer	Oppenheimer	Buy Reiterates $11 → $12	Buy	Reiterates	$11 → $12	+4,009.59%	Mar 28, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 96.53M

Revenue Next Year

n/a

EPS This Year

-0.65

from -1.40

EPS Next Year

-0.71

from -0.65

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028	FY 2029
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028	Dec 31, 2029
Revenue	8.24M	25.38M	163.90M	53.64M	96.53M
Revenue Growth	-	208.14%	545.83%	-67.27%	79.95%	-	-	-
EPS	-7.62	-4.35	-4.51	-3.50	-1.40	-0.65	-0.71	-0.72
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	6	6	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	33.9M	104.5M	233.5M
Avg	8.2M	25.4M	163.9M
Low	n/a	n/a	122.0M

Revenue Growth

Revenue Growth	2025	2026	2027
High	-64.9%	1,168.8%	819.9%
Avg	-91.5%	208.1%	545.8%
Low	-	-	380.8%

EPS Forecast

EPS	2025	2026	2027
High	-0.66	-0.63	-0.60
Avg	-0.65	-0.71	-0.72
Low	-0.64	-0.84	-0.89

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.